Why Analysts Remain Bullish On This Hemophilia Gene-Therapy Play – Investor’s Business Daily
Investor’s Business Daily |
Why Analysts Remain Bullish On This Hemophilia Gene–Therapy Play
Investor’s Business Daily The biotech company is researching a gene therapy called valoctocogene roxaparvovec, or valrox, in patients with hemophilia A. Patients with hemophilia A are missing or have low levels of a clotting protein called Factor VIII. Valrox aims to bring … Momentum grows for hemophilia gene therapies |
